Journal information | translational psychiatry

On this page: Aims & scope of journal | Why publish with _Translational Psychiatry_? | Journal metrics | Abstracted/indexed in | ISSN and E-ISSN WHY PUBLISH IN _TRANSLATIONAL

PSYCHIATRY_? * Bridges the gap between research in neuroscience and conceptually novel treatments. * Highly respected global Editorial Board. * High visibility due to open access. AIMS AND

SCOPE OF JOURNAL Psychiatry has been held back by our limited translational pipeline. Nobel laureate Julius Axelrod's discovery in 1961 of monoamine reuptake by pre-synaptic neurons

still forms the basis of most commonly prescribed types of antidepressants treatment. Likewise, dopamine receptor antagonists are widely used to treat schizophrenia. Pierre Deniker and Jean

Delay conducted a clinical trial at the Sainte-Anne Hospital Center in Paris in which they treated 38 psychotic patients with daily injections of chlorpromazine, a dopamine receptor

antagonist, without the use of other sedating agents. The response was dramatic; treatment with chlorpromazine went beyond simple sedation with patients showing improvements in thinking and

emotional behavior. That was first reported in 1952. There is a grievous gap between the explosion of knowledge in neuroscience and conceptually novel treatments for our patients that will

result in better outcomes than what is provided by existing approaches. _Translational Psychiatry_ bridges this gap by focusing on papers that directly study psychiatric disorders and bring

new discovery into clinical practice. In addition to this core mission of the journal, we may consider papers from all areas of medical research, including — but not restricted to —

molecular biology, genetics, pharmacology, imaging, and epidemiology, that have potential to contribute to enhance the field of translational psychiatry more broadly. To maintain balance,

such papers that do not directly address our core mission will be considered on a case-by-case basis, as a matter of editorial discretion, which can also be supported by advice gained during

the peer review process. WE ARE THE HIGHEST-RANKED OPEN ACCESS JOURNAL IN PSYCHIATRY, WITH THE AIM OF BRIDGING THE GAP BETWEEN THE EXPLOSION OF KNOWLEDGE IN NEUROSCIENCE AND CONCEPTUALLY

NOVEL TREATMENTS FOR OUR PATIENTS. OPEN ACCESS publication ensures that YOUR ARTICLE CAN BE EASILY DISCOVERED, ACCESSED, USED, AND SHARED, MAXIMIZING YOUR IMPACT and acting as a springboard

for further discovery. We provide a CLEAR AND SUPPORTIVE PUBLICATION PROCESS, and ensure HIGH VISIBILITY for your publication through our nature.com platform. Our HIGHLY-RESPECTED EDITORIAL

TEAM leads a rigorous and rapid peer review process. JOURNAL METRICS Article metrics such as number of downloads, citations and online attention are available from each article page, and

provide an overview of the attention received by a paper. CITATION IMPACT 2023 * Journal Impact Factor: 5.8 * 5-year Journal Impact Factor: 6.3 * Source Normalized Impact per Paper (SNIP):

1.457 * SCImago Journal Rank (SJR): 2.203 SPEED 2024 * Submission to first editorial decision (median days): 22 * Submission to acceptance (median days): 219 USAGE 2024 * Downloads:

6,537,481 * Altmetric mentions: 8,745 More about our metrics ABSTRACTED/INDEXED IN PubMed/MEDLINE PubMed Central Scopus ISI Web of Science DOAJ British Library Crossref ISSN AND E-ISSN The

ISSN (online) number for _Translational Psychiatry_ is 2158-3188.